Composition for treating lung cancer and preparation method thereof
Through fermentation, ginseng saponin is extracted and cocrystalline with other plant components and adsorbed on modified porous silica particles. Combined with fermented probiotics, a lung cancer treatment composition with slow-release effect is prepared, solving the drug resistance in lung cancer treatment. and stability issues have achieved better anti-lung cancer effects and reduced toxic and side effects.
Patent Information
- Application Number
- CN202411080446.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
AI Technical Summary
Among the existing lung cancer treatment methods, chemotherapy drug resistance and recurrence and metastasis are still urgent issues that need to be solved, and the application of traditional Chinese medicine in the comprehensive treatment of lung cancer has the problems of low content of rare saponins and poor drug stability.
Ginseng saponin was extracted by fermenting ginseng, and adsorbed with quercetin, kaempferol, luteolin, baicalin, baicalin, and sodium pyridium vitamin B6 onto modified porous silica particles, combined with embedded fermentation probiotics , and prepare a composition for treating lung cancer with a slow-release effect.
It improves the bioavailability and stability of the drug, enhances the antioxidant, anti-inflammatory and anti-tumor immune response effects, delays the progress of lung cancer, and reduces the toxic and side effects of the drug.
Smart Images

Figure BDA0004986120460000191 
Figure BDA0004986120460000201
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a composition for treating lung cancer and a preparation method thereof. Background Art
[0002] Lung cancer is the leading cause of cancer-related deaths that seriously threatens human health worldwide, and non-small cell lung cancer accounts for about 85% of all subtypes. Based on surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy, the recurrence and metastasis of lung cancer are still clinical problems that need to be solved urgently. Traditional Chinese medicine has shown unique advantages in the comprehensive treatment of lung cancer. After clinical trials based on the concept of evidence-based medicine, traditional Chinese medicine has a positive effect on delaying the recurrence of lung cancer and regulating the body's immunity.
[0003] A large amount of clinical drug use experience and laboratory studies have shown that combination therapy can solve the problem of anti-tumor drug resistance to some extent, and combination therapy has many advantages over single-drug therapy, such as overcoming tumor resistance, producing synergistic effects, and reducing toxic side effects. However, how to select a combination that can have a synergistic effect and reduce drug resistance from the vast number of drugs has become a new challenge faced by scientists in the field of drug research and development. Summary of the invention
[0004] The purpose of the present invention is to provide a composition for treating lung cancer and a preparation method thereof, which can effectively resist tumor immune response, play a good antioxidant and anti-inflammatory role, and has high bioavailability, sustained-release effect, good stability, improved efficacy and patient compliance, and has broad application prospects.
[0005] The technical solution of the present invention is achieved in this way:
[0006] The invention provides a method for preparing a composition for treating lung cancer. The method comprises the following steps: fermenting ginseng, separating ginsenosides with ionic liquids to obtain ginsenosides, preparing quercetin-kaempferol-luteolin-wogonin-baicalein cocrystals, and adsorbing the quercetin-kaempferol-luteolin-wogonin-baicalein cocrystals together with sodium cantharidin and vitamin B6 on tannic acid-modified porous silica particles, and uniformly mixing the quercetin-kaempferol-luteolin cocrystals with embedded fermented probiotics to obtain a composition for treating lung cancer.
[0007] As a further improvement of the present invention, the following steps are included:
[0008] S1. Fermentation, extraction and purification of ginseng: adding ginseng powder to water, sterilizing, inoculating fermentation bacteria for fermentation, filtering, washing the solid, concentrating the washing liquid to obtain a fermented probiotic liquid, adding an ionic liquid to the liquid, introducing CO2 to increase the polarity, stirring and extracting, layering, collecting the ionic liquid layer, heating to dissipate CO2, layering, collecting the non-ionic liquid layer, and drying to obtain ginsenosides;
[0009] S2. Preparation of cocrystals: dissolving quercetin in acetone to obtain solution A, dissolving kaempferol in ether to obtain solution B, dissolving luteolin in 10-12 wt% NaOH solution to obtain solution C, dissolving wogonin in dichloromethane to obtain solution D, and dissolving baicalin in ethanol to obtain solution E; mixing solution A, solution B, solution C, solution D, and solution E uniformly, evaporating the solvent in an open state, filtering the crystals, washing the crystals, and ball milling to obtain cocrystals;
[0010] S3. Preparation of porous silica particles: alkyl orthosilicate, porogen, ethanol and water are mixed uniformly, the pH value of the solution is adjusted to be alkaline, stirred to form a gel, dried, calcined, and ball-milled to obtain porous silica particles;
[0011] S4. Tannic acid modification: adjusting the pH of the aqueous solution with a Tris-HCl solution and a base, adding porous silica particles and tannic acid, heating and stirring to react, filtering, washing, and drying to obtain modified porous silica particles;
[0012] S5. Preparation of encapsulated fermented probiotics: adding whey protein and lecithin to the fermented probiotic solution, emulsifying, adding to the wall material solution, emulsifying, treating in an ice water bath, collecting small particles, washing, freeze-drying, and obtaining encapsulated fermented probiotics;
[0013] S6. Preparation of adsorption particles: adding ginsenoside, cocrystal, sodium cantharidin vitamin B6 and modified porous silica particles to an ethanol aqueous solution, stirring for adsorption, and evaporating the solvent to obtain adsorption particles;
[0014] S7. Preparation of a composition for treating lung cancer: stirring and mixing the embedded fermented probiotics and the adsorbed particles to obtain a composition for treating lung cancer.
[0015] As a further improvement of the present invention, the solid-liquid ratio of ginseng powder and water in step S1 is 1:7-10 g / mL, the fermentation bacteria are Bacillus subtilis and Saccharomyces cerevisiae, the fermentation conditions are 40-45°C, 100-200 r / min, the fermentation culture is 36-48 h, the ionic liquid is 1-hexyl-3-methylimidazolium tetrafluoroborate, the CO2 ventilation rate is 10-20 mL / min, the stirring extraction time is 1-2 h, the heating temperature is 40-50°C, and the bacterial content of the fermented probiotic solution is 10 9 -10 10 cfu / mL.
[0016] As a further improvement of the present invention, the mass ratio of quercetin, kaempferol, luteolin, wogonin and baicalein in step S2 is 0.5-1:0.3-0.5:0.2-0.4:0.1-0.2:0.3-0.5.
[0017] As a further improvement of the present invention, the alkyl orthosilicate in step S3 is methyl orthosilicate or ethyl orthosilicate, the mass ratio of the alkyl orthosilicate, the porogen, ethanol and water is 12-16:0.5-1:80-100:10-15, the pH value of the adjusted solution is 9-10, the calcination temperature is 500-600°C, the time is 2-4h, and the ball milling time is 1-2h.
[0018] As a further improvement of the present invention, the pH value of the aqueous solution is adjusted to 8.5-9.5 in step S4, the mass ratio of the porous silica particles to tannic acid is 15-20:7-10, the temperature of the heating and stirring reaction is 45-55°C, and the time is 3-5h.
[0019] As a further improvement of the present invention, the volume ratio of the fermented probiotic solution and the wall material solution in step S5 is 1:2, and the wall material solution is prepared by dissolving polyacrylic acid resin II and polyacrylic acid resin III in dichloromethane at a mass ratio of 3:1-2, adding lecithin, stirring and mixing evenly, to obtain the wall material solution.
[0020] As a further improvement of the present invention, the mass ratio of ginsenoside, cocrystal, sodium cantharidin vitamin B6 and modified porous silica particles in step S6 is 1-2:0.5-1:0.2-0.3:10.
[0021] As a further improvement of the present invention, the mass ratio of the embedded fermented probiotics to the adsorption particles in step S7 is 10:13-15.
[0022] The present invention further protects a composition for treating lung cancer prepared by the above preparation method.
[0023] The present invention has the following beneficial effects:
[0024] Tissue damage caused by inflammation can trigger and promote the development of lung cancer. In the present invention, ginsenosides have a strong lung protective effect, among which ginsenosides Rb1, Rg3 and Rg1 can target nuclear factor κB, transcription factor Nrf2, mitogen-activated protein kinase MAPK and phosphatidylinositol 3-kinase PI3K / protein kinase B pathway to relieve inflammation and oxidative stress. Rare ginsenosides can be used as both anti-lung cancer agents and lung protective agents, and can inhibit lung cancer cell proliferation, induce apoptosis, regulate autophagy, inhibit invasion and metastasis, inhibit epithelial-mesenchymal transition and angiogenesis, regulate immunity, inhibit drug resistance, enhance chemotherapy sensitivity and efficacy, and have the effect of delaying lung cancer. However, the content of rare ginsenosides in ordinary ginseng is low, and it cannot play a good regulatory role. After the synergistic fermentation of fermentation bacteria, ordinary saponins can be converted into rare saponins, which greatly improves the effect of the product against lung cancer, and improves its effect of relieving inflammation, oxidative stress, and delaying lung cancer.
[0025] However, the product obtained by the fermentation method also contains a lot of other substances, including a lot of water-soluble sugars, amino acids, etc., which increases the difficulty of purifying ginsenosides. The present invention uses a water-insoluble ionic liquid for extraction, and increases the polarity of the ionic liquid by introducing CO2, so that the selectivity for ginsenosides is higher. By heating and escaping CO2, ginsenosides and ionic liquids are separated, and the obtained product has high purity and high extraction efficiency.
[0026] Quercetin can activate tumor suppressor genes, inhibit the activity of tumor cells, inhibit the formation of tumor blood vessels, regulate the cell cycle, inhibit tumor growth and invasion, and can damage DNA through the mitochondrial pathway and activate the pro-oxidative properties of cells. Quercetin can inhibit the expression of STAT3 and p-STAT3 proteins by inhibiting the signal transducer and activator of transcription 3 signaling pathway, thereby inhibiting the proliferation, migration and invasion of lung cancer cells. Kaempferol has the effect of inhibiting the invasion and metastasis of lung cancer, inhibiting the epithelial-mesenchymal transition of lung cancer cells, and directly inhibiting tumor metastasis by blocking the formation of NETs by inhibiting the ROSAD4 pathway. Luteolin can inhibit the proliferation, invasion and migration of lung cancer A549 cells and induce cell apoptosis. Wogonin can induce apoptosis of lung cancer cells by activating Caspase, promoting the cleavage level of PARP in A549 and A427 cells, and increasing the generation of ROS. Baicalein induces apoptosis and autophagy of lung cancer cells by inducing the loss of MMP, the release of cytochrome c and Aif from mitochondria to cytoplasm, affecting the activation of AMPK pathway and inhibiting Scr phosphorylation. Therefore, this type of compound not only has a broad source, but also has a good effect of resisting lung cancer. However, compounds such as quercetin, kaempferol, luteolin, wogonin, and baicalein have poor water solubility and poor stability, thereby affecting their bioavailability. The present invention prepares drug cocrystals by co-crystallization growth, significantly improves the solubility of poorly soluble drugs, thereby improving their bioavailability, improving their thermal stability and chemical stability, and can also achieve slow and controlled release, which helps to enhance the efficacy of the drug.
[0027] Porous silica particles are prepared by the sol-gel method, which have a large specific surface area and abundant pores, making it easy to adsorb drugs. However, they are prone to falling off and have poor adsorption stability. Therefore, their surfaces are modified with tannic acid to have abundant active groups such as carboxyl groups, which can form relatively stable complexes with ginsenosides, cocrystals, and sodium cantharidin vitamin B6 by forming hydrogen bonds. On the one hand, they release drugs through controlled release, and on the other hand, they also increase the drug loading capacity.
[0028] The present invention uses polyacrylic acid resin (II, III) as an embedding agent to form an elastic gel with a network structure. After the whey protein contacts the elastic gel, a thixotropic gel is formed, and the solubility changes with the pH value of the solution. The whey protein condenses and precipitates in the gastric acid solution, dissolves in the alkaline environment of the intestine, and gradually peels off to release the fermented bacteria in the embedding layer, thereby realizing the intestinal fixed-point release of the fermented probiotics. The fermented probiotics can regulate the imbalance of intestinal flora, activate the immune system in the body, regulate the functions of T cells and dendritic cells, and promote the expression of prostaglandin E2, thereby exerting an anti-inflammatory effect and promoting anti-cancer, anti-inflammatory, and anti-mutagenic effects.
[0029] The present invention also adds an important raw material, sodium cantharidinate vitamin B6, which can change T cell subpopulations to promote the body to produce effective anti-tumor immune response, stimulate macrophages, lymphocytes and polymorphonuclear leukocytes to produce interleukins, regulate intestinal immune function, improve the body's immune response, promote the maturation of bone marrow hematopoietic stem cells, and reduce the toxic and side effects of chemotherapy, but cannot prolong the patient's survival.
[0030] The composition for treating lung cancer prepared by the present invention can effectively resist tumor immune response, play a good antioxidant and anti-inflammatory role, and has high bioavailability, sustained-release effect, good stability, improved drug efficacy and patient compliance, and has broad application prospects. DETAILED DESCRIPTION
[0031] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Bacillus subtilis, 20 billion cfu / g, was purchased from Shandong Pingju Biotechnology Co., Ltd., and Saccharomyces cerevisiae, 20 billion cfu / g, was purchased from Angel Yeast Co., Ltd.
[0033] Preparation method of Bacillus subtilis and Saccharomyces cerevisiae seed solution: inoculate the strains into a slant culture medium, activate and culture at 40°C, 100 r / min for 24 hours, and obtain a culture medium with a bacterial content of 10 8 -10 9 cfu / mL of bacterial seed solution.
[0034] Polyacrylic acid resin II, brand, Sigma, Polyacrylic acid resin III, brand, source Leaf Biotechnology.
[0035] Example 1
[0036] This embodiment provides a method for preparing a composition for treating lung cancer, comprising the following steps:
[0037] S1. Fermentation, extraction and purification of ginseng: 10 g ginseng powder was added to 70 mL water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquid, the inoculation amount was 1 v / v% and 2 v / v%, respectively, at 40°C, 100 r / min, fermented and cultured for 36 h, filtered, solid washed, and the washing liquid was concentrated to obtain a fermented probiotic liquid, an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate was added to the liquid, CO2 was introduced at a ventilation rate of 10 mL / min, the polarity was increased, stirred and extracted for 1 h, layered, the ionic liquid layer was collected, heated to a temperature of 40°C, CO2 was released, layered, the non-ionic liquid layer was collected, and dried to obtain ginsenosides;
[0038] S2. Preparation of cocrystals: 0.5 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.3 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.2 g of luteolin was dissolved in 100 mL of 10 wt% NaOH solution to obtain solution C, 0.1 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.3 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0039] S3. Preparation of porous silica particles: 12 g of tetraethyl orthosilicate, 0.5 g of porogen hexadecyltrimethylammonium chloride, 80 g of ethanol and 10 g of water were mixed uniformly, the pH value of the solution was adjusted to 9, stirred to form a gel, dried, calcined at 500 ° C for 2 h, and ball milled for 1 h to obtain porous silica particles;
[0040] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 15 g of porous silica particles and 7 g of tannic acid were added, heated to 45 ° C, stirred for 3 h, filtered, washed, and dried to obtain modified porous silica particles;
[0041] S5. Preparation of encapsulated fermented probiotics: 3 g of whey protein and 0.1 g of lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0042] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 2 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0043] S6. Preparation of adsorption particles: 1 g of ginsenoside, 0.5 g of eutectic, 0.2 g of sodium cantharidin vitamin B6 and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorption particles;
[0044] S7. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 6.5 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0045] Example 2
[0046] This embodiment provides a method for preparing a composition for treating lung cancer, comprising the following steps:
[0047] S1. Fermentation, extraction and purification of ginseng: 10 g ginseng powder was added to 100 mL water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquid, the inoculation amount was 2 v / v% and 3 v / v%, respectively, at 45°C, 200 r / min, fermented and cultured for 48 h, filtered, solid washed, and the washing liquid was concentrated to obtain a fermented probiotic liquid, an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate was added to the liquid, CO2 was introduced at a ventilation rate of 20 mL / min, the polarity was increased, stirred and extracted for 2 h, layered, the ionic liquid layer was collected, heated to a temperature of 50°C, CO2 was released, layered, the non-ionic liquid layer was collected, and dried to obtain ginsenosides;
[0048] S2. Preparation of cocrystals: 1 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.5 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.4 g of luteolin was dissolved in 100 mL of 12 wt% NaOH solution to obtain solution C, 0.2 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.5 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0049] S3. Preparation of porous silica particles: 16 g of tetraethyl orthosilicate, 1 g of porogen hexadecyltrimethylammonium chloride, 100 g of ethanol and 15 g of water were mixed uniformly, the pH value of the solution was adjusted to 10, stirred to form a gel, dried, calcined at 600 ° C for 4 h, and ball milled for 2 h to obtain porous silica particles;
[0050] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 20 g of porous silica particles and 10 g of tannic acid were added, heated to 55 ° C, stirred for 5 h, filtered, washed, and dried to obtain modified porous silica particles;
[0051] S5. Preparation of encapsulated fermented probiotics: 5 g of whey protein and 0.2 g of lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0052] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 4 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0053] S6. Preparation of adsorption particles: 2 g of ginsenosides, 1 g of eutectic, 0.3 g of sodium cantharidin vitamin B6 and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorption particles;
[0054] S7. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 7.5 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0055] Example 3
[0056] This embodiment provides a method for preparing a composition for treating lung cancer, comprising the following steps:
[0057] S1. Fermentation, extraction and purification of ginseng: 10 g of ginseng powder was added to 85 mL of water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquids, with inoculation amounts of 1.5 v / v% and 2.5 v / v%, respectively, at 42°C, 150 r / min, fermented for 42 h, filtered, solid washed, and the washing liquid concentrated to obtain a fermented probiotic liquid, an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate was added to the liquid, CO2 was introduced at a ventilation rate of 15 mL / min, the polarity was increased, stirred and extracted for 1.5 h, separated, the ionic liquid layer was collected, heated to a temperature of 45°C, CO2 was released, separated, the non-ionic liquid layer was collected, and dried to obtain ginsenosides;
[0058] S2. Preparation of cocrystals: 0.7 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.4 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.3 g of luteolin was dissolved in 100 mL of 11 wt% NaOH solution to obtain solution C, 0.15 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.4 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0059] S3. Preparation of porous silica particles: 14 g of tetraethyl orthosilicate, 0.7 g of porogen hexadecyltrimethylammonium chloride, 90 g of ethanol and 12 g of water were mixed uniformly, the pH value of the solution was adjusted to 9.5, stirred to form a gel, dried, calcined at 550 ° C for 3 h, and ball milled for 1.5 h to obtain porous silica particles;
[0060] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 17 g of porous silica particles and 8.5 g of tannic acid were added, heated to 50 ° C, stirred for 4 h, filtered, washed, and dried to obtain modified porous silica particles;
[0061] S5. Preparation of encapsulated fermented probiotics: 4 g whey protein and 0.15 g lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0062] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 3 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0063] S6. Preparation of adsorbed particles: 1.5 g of ginsenosides, 0.7 g of eutectic, 0.25 g of sodium cantharidin vitamin B6 and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorbed particles;
[0064] S7. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 7 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0065] Comparative Example 1
[0066] Compared with Example 3, the difference is that fermentation bacteria are not inoculated for fermentation in step S1.
[0067] The details are as follows:
[0068] S1. Extraction and purification of ginseng: add 10g ginseng powder to 85mL water, heat to boiling and extract for 2h, add an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate to the liquid, introduce CO2 at a flow rate of 15mL / min, increase the polarity and stir to extract for 1.5h, separate the layers, collect the ionic liquid layer, heat to 45°C, release CO2, separate the layers, collect the non-ionic liquid layer, and dry to obtain ginsenosides;
[0069] S2. Preparation of cocrystals: 0.7 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.4 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.3 g of luteolin was dissolved in 100 mL of 11 wt% NaOH solution to obtain solution C, 0.15 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.4 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0070] S3. Preparation of porous silica particles: 14 g of tetraethyl orthosilicate, 0.7 g of porogen hexadecyltrimethylammonium chloride, 90 g of ethanol and 12 g of water were mixed uniformly, the pH value of the solution was adjusted to 9.5, stirred to form a gel, dried, calcined at 550 ° C for 3 h, and ball milled for 1.5 h to obtain porous silica particles;
[0071] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 17 g of porous silica particles and 8.5 g of tannic acid were added, heated to 50 ° C, stirred for 4 h, filtered, washed, and dried to obtain modified porous silica particles;
[0072] S5. Preparation of encapsulated fermented probiotics: 4 g whey protein and 0.15 g lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0073] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 3 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0074] S6. Preparation of adsorbed particles: 1.5 g of ginsenosides, 0.7 g of eutectic, 0.25 g of sodium cantharidin vitamin B6 and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorbed particles;
[0075] S7. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 7 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0076] Comparative Example 2
[0077] Compared with Example 3, the difference is that no ionic liquid extraction is used in step S1.
[0078] The details are as follows:
[0079] S1. Fermentation, extraction and purification of ginseng: 10 g ginseng powder was added to 85 mL water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquid, the inoculation amount was 1.5 v / v% and 2.5 v / v%, respectively, at 42 ° C, 150 r / min, fermented for 42 h, filtered, solid washed, washing liquid concentrated to obtain fermented probiotic liquid, liquid dried to obtain ginseng extract;
[0080] S2. Preparation of cocrystals: 0.7 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.4 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.3 g of luteolin was dissolved in 100 mL of 11 wt% NaOH solution to obtain solution C, 0.15 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.4 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0081] S3. Preparation of porous silica particles: 14 g of tetraethyl orthosilicate, 0.7 g of porogen hexadecyltrimethylammonium chloride, 90 g of ethanol and 12 g of water were mixed uniformly, the pH value of the solution was adjusted to 9.5, stirred to form a gel, dried, calcined at 550 ° C for 3 h, and ball milled for 1.5 h to obtain porous silica particles;
[0082] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 17 g of porous silica particles and 8.5 g of tannic acid were added, heated to 50 ° C, stirred for 4 h, filtered, washed, and dried to obtain modified porous silica particles;
[0083] S5. Preparation of encapsulated fermented probiotics: 4 g whey protein and 0.15 g lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0084] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 3 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0085] S6. Preparation of adsorbent particles: 1.5 g of ginseng extract, 0.7 g of eutectic, 0.25 g of sodium cantharidin vitamin B6 and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorbent particles;
[0086] S7. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 7 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0087] Comparative Example 3
[0088] Compared with Example 3, the difference is that in step S2, the components are simply mixed.
[0089] The details are as follows:
[0090] S1. Fermentation, extraction and purification of ginseng: 10 g of ginseng powder was added to 85 mL of water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquids, with inoculation amounts of 1.5 v / v% and 2.5 v / v%, respectively, at 42°C, 150 r / min, fermented for 42 h, filtered, solid washed, and the washing liquid concentrated to obtain a fermented probiotic liquid, an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate was added to the liquid, CO2 was introduced at a ventilation rate of 15 mL / min, the polarity was increased, stirred and extracted for 1.5 h, separated, the ionic liquid layer was collected, heated to a temperature of 45°C, CO2 was released, separated, the non-ionic liquid layer was collected, and dried to obtain ginsenosides;
[0091] S2. Preparation of a mixture: 0.7 g of quercetin, 0.4 g of kaempferol, 0.3 g of luteolin, 0.15 g of wogonin, and 0.4 g of baicalin were mixed for 20 min to obtain a mixture;
[0092] S3. Preparation of porous silica particles: 14 g of tetraethyl orthosilicate, 0.7 g of porogen hexadecyltrimethylammonium chloride, 90 g of ethanol and 12 g of water were mixed uniformly, the pH value of the solution was adjusted to 9.5, stirred to form a gel, dried, calcined at 550 ° C for 3 h, and ball milled for 1.5 h to obtain porous silica particles;
[0093] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 17 g of porous silica particles and 8.5 g of tannic acid were added, heated to 50 ° C, stirred for 4 h, filtered, washed, and dried to obtain modified porous silica particles;
[0094] S5. Preparation of encapsulated fermented probiotics: 4 g whey protein and 0.15 g lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0095] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 3 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0096] S6. Preparation of adsorption particles: 1.5 g of ginsenosides, 0.7 g of the mixture, 0.25 g of sodium cantharidin and vitamin B6, and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorption particles;
[0097] S7. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 7 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0098] Comparative Example 4
[0099] Compared with Example 3, the difference is that step S4 is not performed.
[0100] The details are as follows:
[0101] S1. Fermentation, extraction and purification of ginseng: 10 g of ginseng powder was added to 85 mL of water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquids, with inoculation amounts of 1.5 v / v% and 2.5 v / v%, respectively, at 42°C, 150 r / min, fermented for 42 h, filtered, solid washed, and the washing liquid concentrated to obtain a fermented probiotic liquid, an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate was added to the liquid, CO2 was introduced at a ventilation rate of 15 mL / min, the polarity was increased, stirred and extracted for 1.5 h, separated, the ionic liquid layer was collected, heated to a temperature of 45°C, CO2 was released, separated, the non-ionic liquid layer was collected, and dried to obtain ginsenosides;
[0102] S2. Preparation of cocrystals: 0.7 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.4 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.3 g of luteolin was dissolved in 100 mL of 11 wt% NaOH solution to obtain solution C, 0.15 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.4 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0103] S3. Preparation of porous silica particles: 14 g of tetraethyl orthosilicate, 0.7 g of porogen hexadecyltrimethylammonium chloride, 90 g of ethanol and 12 g of water were mixed uniformly, the pH value of the solution was adjusted to 9.5, stirred to form a gel, dried, calcined at 550 ° C for 3 h, and ball milled for 1.5 h to obtain porous silica particles;
[0104] S4. Preparation of encapsulated fermented probiotics: 4 g whey protein and 0.15 g lecithin were added to 100 mL of fermented probiotic solution, emulsified at 8000 r / min for 15 min, added to 200 mL of wall material solution, emulsified at 8000 r / min for 15 min, treated in an ice water bath, small particles were collected, washed, and freeze-dried to obtain encapsulated fermented probiotics;
[0105] The wall material solution is prepared by dissolving 6 g of polyacrylic acid resin II and 3 g of polyacrylic acid resin III in 200 mL of dichloromethane according to a mass ratio, adding 0.05 g of lecithin, and stirring and mixing for 30 minutes to obtain a wall material solution;
[0106] S5. Preparation of adsorption particles: 1.5 g ginsenoside, 0.7 g eutectic, 0.25 g sodium cantharidin vitamin B6 and 10 g porous silica particles were added to 200 mL 60 wt % ethanol aqueous solution, stirred for 20 min, and the solvent was evaporated to obtain adsorption particles;
[0107] S6. Preparation of a composition for treating lung cancer: 5 g of embedded fermented probiotics and 7 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0108] Comparative Example 5
[0109] Compared with Embodiment 3, the difference is that step S5 is not performed.
[0110] The details are as follows:
[0111] S1. Fermentation, extraction and purification of ginseng: 10 g ginseng powder was added to 85 mL water, sterilized, inoculated with Bacillus subtilis and Saccharomyces cerevisiae seed liquid, the inoculation amount was 1.5 v / v% and 2.5 v / v%, respectively, at 42°C, 150 r / min, fermented and cultured for 42 h, filtered, solid washed, and the washing liquid was freeze-dried to obtain fermented probiotics, an equal volume of ionic liquid 1-hexyl-3-methylimidazolium tetrafluoroborate was added to the liquid, CO2 was introduced at a ventilation rate of 15 mL / min, the polarity was increased, stirred and extracted for 1.5 h, layered, the ionic liquid layer was collected, heated to a temperature of 45°C, CO2 was released, layered, the non-ionic liquid layer was collected, and dried to obtain ginsenosides;
[0112] S2. Preparation of cocrystals: 0.7 g of quercetin was dissolved in 100 mL of acetone to obtain solution A, 0.4 g of kaempferol was dissolved in 100 mL of ether to obtain solution B, 0.3 g of luteolin was dissolved in 100 mL of 11 wt% NaOH solution to obtain solution C, 0.15 g of baicalin was dissolved in 100 mL of dichloromethane to obtain solution D, and 0.4 g of baicalin was dissolved in 100 mL of ethanol to obtain solution E; solution A, solution B, solution C, solution D, and solution E were mixed uniformly, the solvent was evaporated in an open state, the crystals were filtered, the crystals were washed, and the crystals were ball-milled to obtain cocrystals;
[0113] S3. Preparation of porous silica particles: 14 g of tetraethyl orthosilicate, 0.7 g of porogen hexadecyltrimethylammonium chloride, 90 g of ethanol and 12 g of water were mixed uniformly, the pH value of the solution was adjusted to 9.5, stirred to form a gel, dried, calcined at 550 ° C for 3 h, and ball milled for 1.5 h to obtain porous silica particles;
[0114] S4. Tannic acid modification: 200 mL of Tris-HCl solution was used to adjust the pH of the aqueous solution with NaOH, 17 g of porous silica particles and 8.5 g of tannic acid were added, heated to 50 ° C, stirred for 4 h, filtered, washed, and dried to obtain modified porous silica particles;
[0115] S5. Preparation of adsorption particles: 1.5 g of ginsenoside, 0.7 g of eutectic, 0.25 g of sodium cantharidin vitamin B6 and 10 g of modified porous silica particles were added to 200 mL of a 60 wt % aqueous ethanol solution, stirred and adsorbed for 20 min, and the solvent was evaporated to obtain adsorption particles;
[0116] S6. Preparation of a composition for treating lung cancer: 5 g of fermented probiotics and 7 g of adsorption particles were stirred and mixed for 10 minutes to prepare a composition for treating lung cancer.
[0117] Test Example 1
[0118] A549 cells in the logarithmic phase were resuspended in complete medium to form 1×10 5 / mL of cell suspension, 100μL of cell suspension was added to a 96-well cell plate, and after culturing for 1 day at 37°C and 5% CO2, drug treatment was performed. The test group was divided into a control group, a cisplatin group, an embodiment 1-3 group, and a comparative example 1-5 group. The drug concentration of the cisplatin group was 5mg / mL; the drug concentration of the embodiment 1-3 group and the comparative example 1-5 group was 50mg / mL. Five duplicate wells were set at the specified drug concentration of each drug, and the drug amount in each well was 150μL. The required cells were placed in a culture facility at 37°C and 5% CO2 and incubated for 48h respectively. During the process, 10μL of 5mg / mL of MTT solution was added to each well, and the culture environment was continued for 4h. The culture environment was cleared, and then about 100μL of DMSO solution was injected into each well, and finally the cell light absorbance (OD) was detected at 490nm of the microplate reader. The above experiment was performed in 3 groups of parallel experiments, and the average value of cell inhibition in each test was calculated to obtain the cell inhibition rate.
[0119] Cell inhibition rate / % = 1-(OD 490 / Control group OD 490 )×100%
[0120] The results are shown in Table 1.
[0121] Table 1
[0122] Group Cell inhibition rate (%) Cisplatin group 39.5 Example 1 79.2 Example 2 80.4 Example 3 80.9 Comparative Example 1 65.2 Comparative Example 2 69.5 Comparative Example 3 57.8 Comparative Example 4 70.8 Comparative Example 5 72.2
[0123] It can be seen from the above table that the compositions for treating lung cancer prepared in Examples 1-3 of the present invention have a good effect of inhibiting lung cancer cells in vitro.
[0124] Test Example 2
[0125] An appropriate amount of LLC cells (mouse lung cancer cells) in the logarithmic growth phase and in good condition were collected, and after a routine digestion procedure, these single cells were adjusted to contain 2×10 per ml with PBS solution. 7The cell suspension was prepared. The injection site of 6-week-old SPF male C57BL / 6 mice weighing 20-24 g was cleaned with an alcohol cotton ball. 0.2 mL of cell suspension was extracted with a syringe and evenly inoculated into the right axillary skin of each mouse. The number of inoculations for each mouse was 4×10 6 LLC cells. Then, the mice were randomly distributed into 10 experimental groups, namely, control group, model group, positive group, Example 1-3 group, and Comparative Example 1-5 group, with 10 mice in each group. The mice were dosed on the second day of inoculation. The positive group was dosed at 3 mg·(kg·d) -1 Cisplatin was intraperitoneally injected; 0.4 mL·(rat·d) was given to the normal group and the model group. -1 The mice were intragastrically administered with 0.5% sodium carboxymethylcellulose solution. The Example 1-3 group and the Comparative Example 1-5 group were administered with 800 mg·(kg·d) -1 The composition for treating lung cancer was administered intragastricly for 14 consecutive days.
[0126] After the drug administration, the solid tumors in the armpits of the mice were completely removed and their weights were measured, and then the average weight of each group was calculated. In addition, the liver and spleen of the mice were extracted and weighed to calculate the organ index.
[0127] The calculation formula is:
[0128] Tumor inhibition rate (%) = (1-tumor mass in the drug administration group / drug administration mass in the model group) × 100%
[0129] Organ index = mouse organ mass / experimental mouse weight
[0130] The results are shown in Table 2.
[0131] Table 2
[0132]
[0133]
[0134] It can be seen from the above table that the compositions for treating lung cancer prepared in Examples 1-3 of the present invention have a higher tumor inhibition rate and have little effect on organ indexes.
[0135] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a composition for treating lung cancer, characterized in that: Ginsenosides are obtained by fermenting ginseng and separating them with ionic liquids, and quercetin-kaempferol-luteolin-wogonin-baicalein cocrystals are prepared. The cocrystals are adsorbed together with sodium cantharidin and vitamin B6 on tannic acid-modified porous silica particles, and then evenly mixed with embedded fermented probiotics to obtain a composition for treating lung cancer.
2. The preparation method according to claim 1, characterized in that: The following steps are involved: S1. Fermentation, extraction and purification of ginseng: adding ginseng powder to water, sterilizing, inoculating fermentation bacteria for fermentation, filtering, washing the solid, concentrating the washing liquid to obtain a fermented probiotic liquid, adding an ionic liquid to the liquid, introducing CO2 to increase the polarity, stirring and extracting, layering, collecting the ionic liquid layer, heating to dissipate CO2, layering, collecting the non-ionic liquid layer, and drying to obtain ginsenosides; S2. Preparation of cocrystals: dissolving quercetin in acetone to obtain solution A, dissolving kaempferol in ether to obtain solution B, dissolving luteolin in 10-12 wt% NaOH solution to obtain solution C, dissolving wogonin in dichloromethane to obtain solution D, and dissolving baicalin in ethanol to obtain solution E; mixing solution A, solution B, solution C, solution D, and solution E uniformly, evaporating the solvent in an open state, filtering the crystals, washing the crystals, and ball milling to obtain cocrystals; S3. Preparation of porous silica particles: alkyl orthosilicate, porogen, ethanol and water are mixed uniformly, the pH value of the solution is adjusted to be alkaline, stirred to form a gel, dried, calcined, and ball-milled to obtain porous silica particles; S4. Tannic acid modification: adjusting the pH of the aqueous solution with a Tris-HCl solution and a base, adding porous silica particles and tannic acid, heating and stirring to react, filtering, washing, and drying to obtain modified porous silica particles; S5. Preparation of encapsulated fermented probiotics: adding whey protein and lecithin to the fermented probiotic solution, emulsifying, adding to the wall material solution, emulsifying, treating in an ice water bath, collecting small particles, washing, freeze-drying, and obtaining encapsulated fermented probiotics; S6. Preparation of adsorption particles: adding ginsenoside, cocrystal, sodium cantharidin vitamin B6 and modified porous silica particles to an ethanol aqueous solution, stirring for adsorption, and evaporating the solvent to obtain adsorption particles; S7. Preparation of a composition for treating lung cancer: stirring and mixing the embedded fermented probiotics and the adsorbed particles to obtain a composition for treating lung cancer.
3. The preparation method according to claim 2, characterized in that: In step S1, the solid-liquid ratio of ginseng powder and water is 1:7-10 g / mL, the fermentation bacteria are Bacillus subtilis and Saccharomyces cerevisiae, the fermentation conditions are 40-45°C, 100-200 r / min, the fermentation culture is 36-48 h, the ionic liquid is 1-hexyl-3-methylimidazolium tetrafluoroborate, the CO2 ventilation rate is 10-20 mL / min, the stirring extraction time is 1-2 h, the heating temperature is 40-50°C, and the bacterial content of the fermented probiotic solution is 10 9 -10 10 cfu / mL.
4. The preparation method according to claim 2, characterized in that: The mass ratio of quercetin, kaempferol, luteolin, wogonin and baicalein in step S2 is 0.5-1:0.3-0.5:0.2-0.4:0.1-0.2:0.3-0.
5.
5. The preparation method according to claim 2, characterized in that: In step S3, the alkyl orthosilicate is methyl orthosilicate or ethyl orthosilicate, the mass ratio of the alkyl orthosilicate, the porogen, ethanol and water is 12-16:0.5-1:80-100:10-15, the pH value of the adjusted solution is 9-10, the calcination temperature is 500-600°C, the time is 2-4h, and the ball milling time is 1-2h.
6. The preparation method according to claim 2, characterized in that: In step S4, the pH value of the aqueous solution is adjusted to 8.5-9.5, the mass ratio of the porous silica particles to tannic acid is 15-20:7-10, the temperature of the heating and stirring reaction is 45-55° C., and the time is 3-5 hours.
7. The preparation method according to claim 2, characterized in that: In step S5, the volume ratio of the fermented probiotic solution to the wall material solution is 1:
2. The wall material solution is prepared by dissolving polyacrylic acid resin II and polyacrylic acid resin III in dichloromethane at a mass ratio of 3:1-2, adding lecithin, and stirring to mix uniformly to obtain the wall material solution.
8. The preparation method according to claim 2, characterized in that: The mass ratio of ginsenoside, cocrystal, sodium cantharidin vitamin B6 and modified porous silica particles in step S6 is 1-2:0.5-1:0.2-0.3:
10.
9. The preparation method according to claim 2, characterized in that: The mass ratio of the embedded fermented probiotics to the adsorbed particles in step S7 is 10:13-15.
10. A composition for treating lung cancer obtained by the preparation method according to any one of claims 1 to 9.
Citation Information
Cited By
Composition for treating gastric cancer as well as preparation method and application thereof
CN119837840A
